Horizon Discovery Announces Two Fresh Licensing Agreements
News Sep 13, 2016
Horizon Discovery Group plc announces the establishment of new partnerships with both the Centre for Process Innovation (CPI) and the National Institute for Bioprocessing Research and Training (NIBRT) to support biologic therapeutic manufacturing in the UK, Ireland and beyond.
Biological therapeutics represented seven of the top ten best selling drugs of 2015, and they feature extensively in developmental pipelines. Access to bioproduction cell lines for their manufacture can be cost prohibitive, and is often restricted in ways that prevent their further optimisation by customers. This stifles innovation and can impede the launch of biological therapeutics due to the challenge of generating bioproduction cell lines that meet the needs of commercial release.
Horizon is using its expertise in genome engineering to improve biological therapeutics manufacturing. As well as developing a tool box of cell lines for the manufacture of a range of current and next generation biological therapeutics, Horizon aims to encourage innovation in other organisations by allowing access to its state of the art bioproduction cell line platform (CHO SOURCE) under flexible licensing terms that include allowing the further modification of cells.
This agreement allows any organisation, through CPI or NIBRT, to access Horizon’s state of the art biomanufacturing cell lines for research purposes, benefiting the global bioprocessing community by allowing access to cutting edge bioproduction cell lines at an early stage of drug or technology development. This initiative reinforces Horizon’s reputation as a leader and innovator, well positioned to support new biomanufacturing programmes whether in the UK or globally.
Upon completion of these studies, it is anticipated that many organisations will continue to use Horizon’s cell lines, thereby establishing a long-term revenue stream for these high value products as they transition to use for commercial manufacture.
Darrin Disley, CEO, Horizon Discovery, commented: “Horizon is committed to driving innovation in bioprocessing. We value the opportunity to work with key industry players including CPI and NIBRT, to ensure that we are delivering the best solutions for our customers and ultimately for patients.”
Fergal O’Brien, Director of Biologics, CPI said: “By providing their cell line for our research use, Horizon, together with the expertise of CPI, will create a powerhouse platform to develop bioprocessing solutions. We’re excited to see the impact that this programme will have.”
Killian O’Driscoll, Director of Projects, NIBRT said: “NIBRT are delighted to interact with Horizon, to combine their excellence and know-how in cell line development with NIBRT’s cutting edge research, which together will provide solutions of real impact for the advancement and improvement of biopharmaceutical manufacturing.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Ancient Syphilis Genomes Decoded for First TimeNews
Researchers recovered three genomes of the bacterium Treponema pallidum from skeletal remains from colonial-era Mexico, and were able to distinguish the subspecies that causes syphilis from the subspecies that causes yaws. It was not previously thought possible to recover DNA from this bacterium from ancient samples.